Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer

Journal of Urology

Volumn 185, Issue 6, 2011, Pages 2376-2381

  Kosaka, Takeo ^a   Miyajima, Akira ^a   Shirotake, Suguru ^a   Suzuki, Eriko ^a   Kikuchi, Eiji ^a   Oya, Mototsugu ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

androgen antagonists; docetaxel; drug resistance; neoplasm; prostate; prostatic neoplasms

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; DOCETAXEL; PROTEIN KINASE B;

ANDROGEN DEPRIVATION THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CASTRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; UPREGULATION;

ANDROGEN ANTAGONISTS; ANIMALS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MICE; MICE, INBRED BALB C; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; PROSTATIC NEOPLASMS; TAXOIDS; TIME FACTORS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 79955847465     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2011.02.016     Document Type: Article

References (14)

1. W.J. Catalona Management of cancer of the prostate N Engl J Med 331 1994 996
2. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2009 CA Cancer J Clin 59 2009 225
3. F. Calabro, and C.N. Sternberg Current indications for chemotherapy in prostate cancer patients Eur Urol 51 2007 17
4. T. Kosaka, A. Miyajima, and S. Shirotake Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer Prostate 70 2010 162
5. T. Kosaka, A. Miyajima, and E. Takayama Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer Prostate 67 2007 41
6. A. Chakravarti, G. Zhai, and Y. Suzuki The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas J Clin Oncol 22 2004 1926
7. L. Hu, J. Hofmann, and Y. Lu Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models Cancer Res 62 2002 1087
8. P. Liu, H. Cheng, and T.M. Roberts Targeting the phosphoinositide 3-kinase pathway in cancer Nat Rev Drug Discov 8 2009 627
9. S.A. Backman, D. Ghazarian, and K. So Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten Proc Natl Acad Sci USA 101 2004 1725
10. A. Di Cristofano, M. De Acetis, and A. Koff Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse Nat Genet 27 2001 222
11. S. Wang, J. Gao, and Q. Lei Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer Cancer Cell 4 2003 209
12. J.I. Kreisberg, S.N. Malik, and T.J. Prihoda Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer Cancer Res 64 2004 5232
13. M.M. Gottesman Mechanisms of cancer drug resistance Annu Rev Med 53 2002 615
14. P.A. Vasey Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies Br J Cancer 89 suppl 2003 S23